Cosmos Health H1 2023 adjusted net income jumps 3550% to $3.01M, revenue down 6%

Cosmos Health Inc.

2023-Q2 EPS reported -$0.13 revenue$24,713,206

Q2 2023 revenue $12.36M (-6.4% YoY); H1 revenue $24.71M (-6.0% YoY) on currency headwinds.
H1 adjusted net income $3.01M vs loss of $0.09M in H1 2022; adjusted EBITDA $3.01M (+182% YoY).
Book value per share exceeds $4.04; stockholders' equity up 12.9% to $44.35M.
Acquired Cana Laboratories (GMP certified) and Bikas distribution network (50 pharmacies, >$10M annual revenue expected).
Property & equipment up 488% to $10.7M; goodwill & intangibles up 435% to $3.78M from Q4 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Cosmos Health Inc. reported second quarter of 2023 results: revenue $12.36 million, net income $0.16 million.

Period: second quarter of 2023
Revenue: $12.36 million
Net income: $0.16 million
Result: reported results

Exact text from the filing

products, and operator of a telehealth platform, today reported its financial results for the second quarter of 2023. Q2 and H1 2023 Financial Highlights · Revenues amounted to $12.36 million in Q2 2023 and $24.71 million in H1 2023, a slight decline of 6.4% and 5.96%, respectively, from $13.21 million and $26.28 million in the corresponding periods in 2022, in part

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Cosmos Health Inc. reported H1 2023 results: revenue $24.71 million, net income $3.01 million.

Period: H1 2023
Revenue: $24.71 million
Net income: $3.01 million
Result: reported results

Exact text from the filing

Revenues amounted to $12.36 million in Q2 2023 and $24.71 million in H1 2023

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Cosmos Health Inc. filing history →

Source: SEC EDGAR

accession 0001477932-23-006179

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.